Good morning, everyone. How are you today? Yet another spot of rain is descending on the Pharmalot corporate campus, where we are laboring to hustle the short people off to their respective school houses. Of course, this calls for the mandatory cup of stimulation - our flavor today is Southern Pecan - which makes it possible to conduct our own version of R&D. We trust you will be equally busy. To get you started, here are some tidbits. Hope your day goes well and stay in touch...
Vertex Gets A Shiny New Headquarters (The Boston Globe)
Johnson & Johnson Buys OTC Brands In Russia (The Business Standard)
AstraZeneca To Co-Promote Amgen Drug In Japan (Reuters)
Younger Docs More Likely To Prescribe Drugs For Heart Disease (HealthDay)
Shire Is Going To Bid For Cubist? (The Telegraph)
UK's NICE OKs Roche's MabThera For Maintenance Therapy (Pharma Times)
Valent To Buy Lithuania's Sanitas For $443M (Reuters)
Another Debate Over Medicating Children (CNN)
Abbott Labs Sued Over Optic Nerve Damage Due To Humira (Bloomberg News)
Medpace Attracts Private Equity Investment (Outsourcing Pharma)
Gilead CEO Discusses Cancer Deal With Yale (Fortune/CNN)
EDITOR’S NOTE: Please check this post for updates throughout the morning
rain pic thx to sterlic on flickr
1 Comment
Younger doctors prescribing more meds may also be related to today's plethora of clinical practice guidelines, which were virtually nonexistent when I was in school. For example, every patient discharged post myocardial infarction from a hospital should be placed on a standard regimen of aspirin, a beta blocker, a statin and an ACE inhibitor as recommended by the ACC. Consistent with the first premise, younger doctors may be more inclined to follow this regimen, although good medicine dicates that you should prescribe this regimen no matter your age.